CNC · Centene Corporation

Medical - Healthcare Plans · mkt cap $29.6B · calls: Q1 FY2026 vs Q4 FY2025

15.0 conviction · conf-adj 15

conf –

enthusiasm:15.0 · trend:-5 · quantifies:0 · impact:0 · under_radar:5 · credibility:0 · business_impact:4 · disruption:0 · commitment:-4 · confirmation:0

Enthusiasm latest 5 / prev 6 (falling)

Centene’s AI narrative is narrow and cost/integrity-focused: fraud/waste detection (75 scoring algorithms; “daily algorithms”), finance forecasting/medical economics as a validation layer, and prior-auth/call-center proof points cited only on the prior call. Enthusiasm softened from CEO-level GenAI/AgenTek framing in Q4 to measured CFO deployment language in Q1, with no analyst AI questions and no quantified revenue, margin, or productivity impact—credibility rests on operational use cases, not disclosed financial outcomes.

PAST (realized)

Q4 FY2025 | Sarah London: Over the last few years, we have been building the necessary data foundation systematically integrating AI into our operations.
Q4 FY2025 | Sarah London: Resulting in proof points around accelerated prior authorization approvals, improved call center operations, enhanced member navigation and engagement experiences, and advanced analytics capabilities that support our medical economics work and our payment integrity operations.

CURRENT (now)

Q1 FY2026 | Andrew Asher: within finance, we are deploying advanced analytics and selective AI-enabled tools across forecasting, medical economics and payment integrity. Today, these capabilities are used as an independent validation layer alongside our traditional forecasting process, bringing more timely data into how we evaluate emerging medical trend. Also helping us identify fraud, waste and abnormal claims behavior earlier, supporting better prioritization of resources and more disciplined cost management on behalf of state and federal tax payers.
Q4 FY2025 | Sarah London: we currently score our claims data against 75 algorithms designed to triangulate potential fraud. Alerts are triggered and sent to a group of cross-functional experts for immediate review and intervention.
Q1 FY2026 | Sarah London: where we're deploying AI and some of those daily algorithms that we run.

FORWARD (guidance)

Q4 FY2025 | Sarah London: As we step into 2026, we are closely tracking the inflection GenAI and accelerating our integration of AgenTek capabilities into our core operations to drive automation and efficiency and using it as a catalyst to reimagine and elevate the we deliver to our members, partners, and other stakeholders.
Q4 FY2025 | Sarah London: You should expect to hear more on this in the quarters ahead.

TRACK RECORD — PROMISE vs DELIVERY

—/100 (no quantified promises) no-quantified-promises 6 calls reviewed

Across Q4 FY2024–Q1 FY2026, Centene cited AI/GenAI (including AgenTek), a 75-algorithm fraud-scoring stack, and faster prior auth as strategy or proof points but never set quantified AI targets with deadlines; delivery on AI promises cannot be scored.

PRICED-IN (REFINED)

MEDIUM

Est. revisions rising · Fwd P/E 29.5 · EV/Sales 0.1x

AI claim maps to Medicaid Segment, Commercial Segment, Other Operating Segment

Estimate momentum is rising: buy ratings increased from five to eight (Jan–May 2026) while holds fell to twelve, and price targets stair-step higher (lastYearAvg 49.06 → lastQuarterAvg 58.77 → lastMonthAvg 69). Consensus already embeds a sharp EPS ramp (2.03 FY25 to 3.48 FY26 to 4.50 FY27) on roughly flat ~$191B revenue, which is consistent with margin/ML efficiency already in the numbers. Valuation is mixed: EV/Sales ~0.1 is not stretched for a mature plan, but ~29.5x forward P/E prices much of the earnings recovery. AI-driven medical-cost and admin gains would most plausibly hit Medicaid and Commercial (and shared cost in Other Operating), so upside is partly reflected in revisions but not fully on a sales basis—medium priced-in.

COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS

5Q4 FY20242Q1 FY20254Q2 FY20253Q3 FY20252Q4 FY20253Q1 FY2026

AI enthusiasm across 6 calls — trend ↘ falling

Explicit AI-for-admin automation opened FY2024; later calls dropped AI talk for data-driven trend management, fraud fighting, and clinical programs.

BUSINESS IMPACT - QUALITATIVE MATERIALITY

5/10 qualitative impact moderate medium-term · soft evidence

Where AI matters: MLR, payment integrity, and admin forecasting

Centene shows real operational AI—75 fraud-scoring algorithms, daily analytics, finance/medical-economics validation, and cited prior-auth/call-center gains—but management offers no revenue, margin, or productivity numbers and tone has cooled from GenAI/AgenTek hype to selective CFO deployment.

Caveats: No quantified AI ROI despite multi-year narrative and AgenTek/GenAI forward promises; Medicaid rate-setting may capture fraud/MLR savings for states rather than Centene shareholders; Prior-auth and navigation automation becoming table stakes, not durable differentiation

AI DISRUPTION / CANNIBALIZATION RISK tailwind · 3/10

Managed Medicaid/commercial insurance economics are driven by premium rates, medical cost, and state contracting—not billable labor AI can erase; AI mainly pressures admin efficiency and competitive MLR parity rather than commoditizing the licensed risk-bearing product.

OPTIONS / MARKET STRUCTURE

option liquidity: good

ATM IV

—

TYPICAL BID-ASK

—

OPEN INTEREST

—

proxy inputs — dollar-ADV $385M · beta 1.062 · px $59.98

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.

CONFIRMATION — INSIDERS · 13F · LANGUAGE

Undercutting — insiders selling, institutions flat, management language 1/10 hedged.

INSIDERS selling 2 open-market sell(s) vs 0 buy(s) — net distribution

INSTITUTIONS (13F) flat as of 2026-03-31: 100 new / 156 closed positions; 406 increased / 348 reduced; institutional ownership -0.80pp; -66 net 13F holders

MGMT LANGUAGE 1/10 hedged Provided excerpt has zero AI/ML/automation statements; only generic data-driven ops language.

VERBATIM AI QUOTES

“One final topic, within finance, we are deploying advanced analytics and selective AI-enabled tools across forecasting, medical economics and payment integrity. Today, these capabilities are used as an independent validation layer alongside our traditional forecasting process, bringing more timely data into how we evaluate emerging medical trend. Also helping us identify fraud, waste and abnormal claims behavior earlier, supporting better prioritization of resources and more disciplined cost management on behalf of state and federal tax payers.”
— Andrew Asher (CFO), Q1 FY2026

“And so we uniquely have an ability to get ahead of that. Drew talked about that in his remarks as well in terms of where we're deploying AI and some of those daily algorithms that we run.”
— Sarah London (CEO), Q1 FY2026

“Taking a step back, our long-term goal across our businesses is to deliver industry-leading outcomes at an industry-leading cost structure. As we create the roadmap to harvest Centene's full potential earnings power, there is no question that data, technology, and artificial intelligence will be a critical lever and accelerant to this work.”
— Sarah London (CEO), Q4 FY2025

“Over the last few years, we have been building the necessary data foundation systematically integrating AI into our operations. Resulting in proof points around accelerated prior authorization approvals, improved call center operations, enhanced member navigation and engagement experiences, and advanced analytics capabilities that support our medical economics work and our payment integrity operations.”
— Sarah London (CEO), Q4 FY2025

“As an example of the latter, we currently score our claims data against 75 algorithms designed to triangulate potential fraud. Alerts are triggered and sent to a group of a cross-functional experts for immediate review and intervention.”
— Sarah London (CEO), Q4 FY2025

“As we step into 2026, we are closely tracking the inflection GenAI and accelerating our integration of AgenTek capabilities into our core operations to drive automation and efficiency and using it as a catalyst to reimagine and elevate the we deliver to our members, partners, and other stakeholders. You should expect to hear more on this in the quarters ahead.”
— Sarah London (CEO), Q4 FY2025